FBLG (40) XCUR (35) ACXP (39) ENVB (37) ⌘ Pro Terminal →

Aprea Therapeutics Inc. (APRE) — RQD Stock Rating Cockpit

$0.49 -8.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.48

Aprea Therapeutics Inc. (APRE) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $6.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.48 (-1.67%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for APRE)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY APRE SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$0.60-3.3% Next Q

Q2 (-2Q)

Grade D$0.58-10.3% Next Q

Q3 (-1Q)

Grade D$0.52-5.8% Next Q

Current

Grade D-$0.49-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a APRE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While APRE currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.70) and Max Pain ($0.51) forces dealer call-delta covering toward $1.56.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $APRE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “APRE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

37.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE7% OF RANGE

L: $0$0.49H: $1

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on APRE

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (30)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (43)

16/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like APRE

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring APRE)

✓Walkthrough of APRE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

APRE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.75%📐 HORIZONTAL RANGE

2026-10-30O $0.48H $0.52L $0.46C $0.49VOL 167.6K

RES: $1.22SUP: $0.40SMA50: $0.70SMA200: $0.75

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

APRE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 APRE Butterfly Map → + Track APRE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on APRE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for APRE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for APRE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APRE)

Health Care Rank #596 of 1016 ⚔️ FBLG vs APRE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (APRE vs. FBLG, XCUR, ACXP, ENVB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aprea Therapeutics Inc. (APRE) ranks #596 by composite RQD confidence (42/100, grade D-) and #925 by equity capitalization ($6.2M). Within this direct 5-issuer industry benchmark cohort, APRE leads on earnings valuation at N/A trailing P/E, while APRE leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APRE currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
APRE ACTIVE Aprea Therapeutics Inc.	D-	42/100	—	—	-35.0%	-8.22%	$6.2M	Benchmark Subject
FBLG FibroBiologics Inc.	D-	40/100	—	—	-35.0%	-3.99%	$6.3M	/fblg-vs-apre →
XCUR Exicure Inc.	D-	35/100	—	—	-35.0%	-8.04%	$6.1M	/xcur-vs-apre →
ACXP Acurx Pharmaceuticals Inc.	D-	39/100	—	—	-35.0%	0.00%	$5.9M	/acxp-vs-apre →
ENVB Enveric Biosciences Inc.	D-	37/100	—	—	-35.0%	-0.68%	$6.5M	/envb-vs-apre →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001781983

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aprea Therapeutics Inc. (APRE) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$12.6M, operating cash flow of -$12.9M, and free cash flow of -$12.9M (+5.0% YoY). On the balance sheet, APRE closed FY2025 with $15.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$12.6M	-$12.9M	-$12.9M	$15.9M	—
FY2024 (FY)	2024-12-31	$0	-$13.0M	-$13.6M	-$13.6M	$24.0M	—
FY2023 (FY)	2023-12-31	$0	-$14.3M	-$12.2M	-$12.2M	—	—

3. APRE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is APRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Aprea Therapeutics Inc. (NASDAQ: APRE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.49 (-8.22% 1D, market cap $6.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, APRE ranks #596 in composite RQD confidence.

How does APRE compare to FBLG and XCUR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APRE carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FBLG (FibroBiologics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $6.3M) and XCUR (Exicure Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $6.1M). Among the 5-stock peer group, APRE leads on earnings multiple (N/A) while APRE leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for APRE?

Per APRE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001781983), Aprea Therapeutics Inc. generated $0 in revenue, -$12.6M in net income, and -$12.9M in free cash flow against $15.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is APRE trading relative to its 50-day, 200-day, and 52-week technical levels?

APRE last traded at $0.49 (-8.22% on volume of 171,057 shares), positioning the stock -30.00% below its 50-day simple moving average ($0.70) and -34.67% below its 200-day simple moving average ($0.75). Across its 52-week range of $0.41 to $1.49, APRE sits at the 7.4% percentile with a 14-day RSI of 37.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.55).

APRE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell APRE stock right now?

Aprea Therapeutics Inc. (APRE) currently earns a Roarable Rating of D- (Sell — SELL) with 42/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is APRE's 12-month price target and RQD AI Jury consensus?

APRE's 12-month base price target is $0.45 (range $0.35 to $1.56), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: APRE RQD Cockpit APRE 12M Forecast APRE Earnings & Move APRE Dividends & DRIP APRE Insiders & 13F APRE Whale Options APRE Profit Sankey APRE News & Why